Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 484 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 31, 2026, 1:10 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 20, 2025 | Feb 21, 2024 | Feb 22, 2023 | Feb 17, 2022 |
| Revenue | $738.3M | $634.4M | $632.4M | $801.5M | $670.5M |
| Cost of revenue | $352.0M | $359.8M | $353.9M | $345.8M | $279.3M |
| Research and development | $54.2M | $43.2M | $42.7M | $43.9M | $34.3M |
| Selling, general and administrative | $290.5M | $263.4M | $218.6M | $215.8M | $183.9M |
| Operating income | $55.2M | -$35.1M | $47.7M | $224.7M | $167.2M |
| Interest expense | $22.6M | – | $1.95M | $1.16M | $12.7M |
| Income tax | $13.5M | -$1.52M | $21.1M | $33.2M | $25.3M |
| Net income | $48.9M | -$25.5M | $35.6M | $186.0M | $128.3M |
| EPS, basic | $0.87 | $-0.46 | $0.64 | $3.35 | $2.33 |
| EPS, diluted | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 |
| Weighted shares, basic | 56.2K | 55.9K | 55.7K | 55.5K | 55.0M |
| Weighted shares, diluted | 56.6K | 55.9K | 56.4K | 57.5K | 57.3M |
| Margins and growth | |||||
| Operating margin | 7.5% | -5.5% | 7.5% | 28.0% | 24.9% |
| Net margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% |
| Revenue growth, year over year | +16.4% | +0.3% | −21.1% | +19.5% | +83.1% |
| Net income growth, year over year | – | −171.7% | −80.9% | +45.0% | +114.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 20, 2025 | Feb 21, 2024 | Feb 22, 2023 | Feb 17, 2022 |
| Cash and equivalents | $566.0M | $757.4M | $751.3M | $523.5M | $603.8M |
| Short-term investments | $201.6M | – | – | – | – |
| Accounts receivable | $158.6M | $134.1M | $124.2M | $116.2M | $117.4M |
| Inventory | $170.5M | $143.0M | $202.3M | $238.3M | $184.5M |
| Total current assets | $1.14B | $1.07B | $1.11B | $998.1M | $931.7M |
| Property, plant and equipment | $186.6M | $197.7M | $207.4M | $190.7M | $125.0M |
| Goodwill | $1.11B | $1.03B | $987.1M | $855.5M | $860.4M |
| Intangible assets | $386.1M | $397.9M | $407.0M | $353.7M | $337.3M |
| Total assets | $2.95B | $2.83B | $2.83B | $2.52B | $2.36B |
| Accounts payable | $30.0M | $32.1M | $19.6M | $27.6M | $36.2M |
| Total current liabilities | $135.8M | $126.8M | $164.9M | $404.2M | $375.3M |
| Long-term debt | $542.2M | – | – | – | – |
| Total liabilities | $843.6M | $856.9M | $866.3M | $614.0M | $608.3M |
| Shareholders' equity | $2.11B | $1.97B | $1.96B | $1.91B | $1.75B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 20, 2025 | Feb 21, 2024 | Feb 22, 2023 | Feb 17, 2022 |
| Operating cash flow | $117.4M | $175.4M | $113.9M | $172.1M | $119.0M |
| Capital expenditures | $23.5M | $25.7M | $36.2M | $84.8M | $67.1M |
| Free cash flow | $93.9M | $149.7M | $77.7M | $87.2M | $51.9M |
| Depreciation and amortization | $78.7M | $69.7M | $68.6M | $51.0M | $38.4M |
| Stock-based compensation | $32.6M | $48.1M | $25.6M | $27.3M | $27.5M |
| Share buybacks | $0 | $0 | $14.4M | – | – |
| Investing cash flow | -$298.5M | -$86.4M | -$123.3M | -$233.2M | -$221.2M |
| Financing cash flow | -$15.2M | -$82.9M | $249.0M | -$13.3M | $961.0K |
| Net change in cash | -$191.3M | $6.03M | $227.9M | -$80.4M | -$113.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.4% | 7.6% | 4.0% | 3.4% | 4.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.